These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 7689174)

  • 1. HIV-1 error revealed.
    Chow YK; Hirsch MS; Kaplan JC; D'Aquila RT
    Nature; 1993 Aug; 364(6439):679. PubMed ID: 7689174
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interaction of primers with mutant forms of human immunodeficiency virus reverse transcriptase].
    Zakharova OD; Suturina OA; Gudima SO; Pokholok DK; Iamkovoĭ VI; Kochetkov SN; Nevinskiĭ GA
    Mol Biol (Mosk); 1996; 30(1):231-40. PubMed ID: 8714140
    [No Abstract]   [Full Text] [Related]  

  • 3. Human immunodeficiency virus. Playing chess with reverse transcriptase.
    Richman DD
    Nature; 1993 Feb; 361(6413):588-9. PubMed ID: 7679776
    [No Abstract]   [Full Text] [Related]  

  • 4. [Stability of human immunodeficiency virus to azidothymidine. II. Kinetic characteristics of "AZT-resistant" mutant forms of reverse transcriptase].
    Pokholok DK; Gudima SO; Memelova LV; Esipov DS; Rechinskiĭ VO; Kochetkov SN
    Biokhimiia; 1996 Jan; 61(1):142-51. PubMed ID: 8679772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
    Naeger LK; Miller MD
    Curr Opin Investig Drugs; 2001 Mar; 2(3):335-9. PubMed ID: 11575701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.
    Fan N; Rank KB; Slade DE; Poppe SM; Evans DB; Kopta LA; Olmsted RA; Thomas RC; Tarpley WG; Sharma SK
    Biochemistry; 1996 Jul; 35(30):9737-45. PubMed ID: 8703945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.
    De Clercq E
    AIDS; 1994 Jul; 8(7):1020-1. PubMed ID: 7524543
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular aspect of HIV-1 resistance to zidovudine and its reversal.
    Camsonne R; Bigot MC; Bustany P; Pottier D; Vergnaud M
    Trends Pharmacol Sci; 1994 May; 15(5):137-8. PubMed ID: 7538701
    [No Abstract]   [Full Text] [Related]  

  • 12. Case report of a novel amino acid deletion in codon 67 and T69G substitution in the reverse transcriptase of HIV-1.
    Giri J; Rueda HJ; Monticelli A; Planes N
    Antivir Ther; 2000 Sep; 5(3):227-8. PubMed ID: 11075943
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.
    Angarano G; Monno L; Appice A; Giannelli A; Romanelli C; Fico C; Pastore G
    AIDS; 1994 Jul; 8(7):1013-4. PubMed ID: 7524541
    [No Abstract]   [Full Text] [Related]  

  • 15. An introduction to HIV drug resistance testing.
    Bean P
    Am Clin Lab; 2000 May; 19(4):10-1. PubMed ID: 10947312
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.
    Devereux HL; Youle M; Johnson MA; Loveday C
    AIDS; 1999 Dec; 13(18):F123-7. PubMed ID: 10630517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
    de Clercq E
    Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
    [No Abstract]   [Full Text] [Related]  

  • 20. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
    Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
    J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.